Elekta Ab Class B · OMXSTO:EKTA_B
Elekta Ab Class B — Investor Day (April 2013)
20 slides from Elekta Ab Class B's investor day presentation, Apr 20, 2013
Slide 1: Elekta Capital Markets Presentation
Elekta Capital Markets Presentation April 20, 2013, Geneva
Slide 2: Agenda; Elekta is stronger than ever
Elekta Capital Markets Presentation AGENDA Tomas Puusepp President and CEO Dee Mathieson S i Vi Senior Vice P President, id t B Business i Li Line O Oncology l Prof. Frederik Wenz MD University Medical Center Mannheim, Department of Radiation Oncology Ian Alexander Executive Vice President, Head of
Slide 3: Strong growth with increased profitability
Strong growth with increased profitability SEK M Net Sales SEK M EBIT Outlook from Q3 report: 10 000 2 000 1 750 8 000 CAGR CAGR 16% 1 500 27% 6 000 1 250 1 000 4 000 750 500 2 000 250 0 0 2005A -06A -07A -08A -09A -10A -11A -12A 2005A -06A -07A -08A -09A -10A -11A -12A Hardware Aftermarket and Soft
Slide 4: Elekta's priorities going forward
Elekta’s priorities going forward • Innovation – R&D – MR-guided linear accelerator • Emerging markets – Availability – Training and education • Leverage installed base Elekta Capital Markets Presentation April 20, 2013, Geneva 3
Slide 5: Versa HD: One Solution. Unlimited Possibilities.
Possibilities. Versa HDTM One Solution. Unlimited P Dee Mathieson Senior Vice President Oncology Business Line Management Unmatched clinically-relevant firsts • Developed p in close collaboration with global thought leaders – Intracranial stereotactic radiosurgery – Digital linac control – Linac-bas
Slide 6: Versa HD, the most advanced digital linear accelerator
Versa HD™ the most advanced digital linear accelerator available 1 Enables higher dose to the tumor 1. - more than three times faster than before 2. Minimizes dose to healthy tissue. MLC leaf speeds more than twice as fast as other systems 3. New g generation of p patient- specific treatments Versa
Slide 7: Improved therapy for more patients
Improved therapy for more patients Leaf speed (cm/s) 7 6 5 Faster MLC leaf speed 4 3 2 1 0 Previous Generation Versa HD TM Improved therapy for more patients Dose rate (Mu/min) 3000 2000 Higher dose rate 1000 0 Previous Versa HD Generation Elekta Linacs 6
Slide 8: High Dose Rate mode
High Dose Rate mode “ Delivery of a non-flattened beam with VMAT Dose rate requires greater leaf velocity. The leaves MU/min need to move very quickly to manage the 5 000 combination of modulation and high dose rates. Up until now, leaf speed has been 4 000 the limiting factor. The full potential of
Slide 9: Fast leaves need accuracy
Fast leaves need accuracy Study of: Leaf velocity limitations related to treatment delivery dosimetric uncertainties for the Varian 120 Millenium MLC inner leaves (5mm width). “ Measurements showed slight deviations from expected within the range from 25mm/s to 33mm/s. At higher hi h leaf l f veloci
Slide 10: Superior target conformance
Superior target conformance • Fully integrated with Elekta Agility® MLC • 160 x 5 mm leaves across the full 40 cm x 40 cm field • Efficiently cover multiple targets with interdigitation and island shapes • Fast leaf speed Image courtesy of Christopher Walker, Head of Radiotherapy Physics The James C
Slide 11: Clinical versatility
Clinical versatility High Multiple stereotactic targets SBRT High dose ratess Dose per fraction e.g. Lung Simple conformal ! e.g. Breast MLC shaping p g capability p y 3 cm/s Longer fields e.g. H&N VMAT Standard Simple Plan Complex Extended high-resolution field shaping Single isocentre, multiple fi
Slide 12: Improved therapy for more patients; Guardian technology
Improved therapy for more patients Higher g dose rate Larger high-definition field size Faster MLC leaf speed • Greater versatility • Improved efficiency • Higher quality patient care Guardian technology 7th generation digital control Audit and safely orchestrate multiple linac functions simultaneou
Slide 13: Elevated patient and clinician experience
Elevated patient and clinician experience c • New ergonomic features • Softer streamlined design Confident and relaxed treatment environment Conserve precious resources 8 000 6 000 • 30% less power consumption 4 000 • Lower operating temperature • Reduced cost of operation 2 000 0 Klystron-based dua
Slide 14: Packages for unique clinical needs; next major breakthrough
Packages for unique clinical needs • Brain & Spine • Head & Neck • Lung • Breast • Prostate Addressing the specific anatomical challenges of radiotherapy Enhancing the Versa HDTM core solution Pioneering the next major breakthrough… State of the art MR imaging state of the art radiation therapy • Bu
Slide 15: Research into MRI-guided radiation therapy
Research into MRI-guided radiation therapy Experimental system at Utrecht, The Netherlands • MRI magnet full on at 1.5T and able to image • Linac able to radiate • MLC able to move leaves • Gantry able to rotate All at the same time! Next steps... Developing a Global Research Consortium • The MRI-GR
Slide 16: Region Europe & AFLAME
Elekta Capital Markets Presentation April 20, 2013, Geneva Region Europe & AFLAME Ian Alexander Executive Vice President Europe & AFLAME 15
Slide 17: Elekta is the market leader in the region
Elekta is the market leader in the region Order development EUR M 500 E Emerging i CAGR market share 400 15% 33% 300 200 100 0 Installed base: 06/07 07/08 08/09 09/10 10/11 11/12 R12 • 1,175 linacs • 50 Leksell Gamma Knife units Market characteristics Emerging Established • Green field expansion • I
Slide 18: Elekta is growing more than the installed base
Elekta is growing more than the installed base Share of order intake Share of installed base FY2011/12 2011/12 Other 6% Other 6% Siemens 4% Siemens 20% 30% Elekta 48% Elekta Varian 42% 44% Varian Market dynamics by key markets Eastern Europe Established Europe • Russia important market and • Mainly
Slide 19: Established markets – market insight
Established markets – market insight • Upgrade of maturing installed base in many markets; Opportunities created by exit of Siemens • Drive usage of radiation therapy on market; In UK only 38% of cancer patients receive RT • In general, Elekta has a strong position in University Hospitals/Clinics; G
Slide 20: Emerging markets – market insight
Emerging markets – market insight • Affordability, Training and Education • Russia: 10-15 clinics are equipped every year; current NOP entering final cycle • Additionally Regional authorities funding 2-4 new RT centers per year • Elekta in planning phase for local manufacturing and E&T Center in Rus